Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

  • Rheumatoid Arthritis
Trial Status:


This trial runs in
  • Amiens
  • Aubenas
  • Belfort
  • Berck
  • Besançon
  • Bordeaux
  • Brest
  • Caen
  • Cahors
  • Caluire-et-Cuire
  • Cannes
  • Castelnaudary
  • Chambray-lès-Tours
  • Clamart
  • Clermont-Ferrand
  • Compiègne
  • Contamine-sur-Arve
  • Corbeil-Essonnes
  • Créteil
  • Dax
  • Dole
  • Douai
  • Dreux
  • Haguenau
  • Juvisy-sur-Orge
  • La Madeleine
  • Laon
  • Le Coudray
  • Le Kremlin-Bicêtre
  • Le Puy-en-Velay
  • Lille
  • Limoges
  • Lyon
  • Marseille
  • Montfermeil
  • Montpellier
  • Morlaix
  • Nice
  • Nogent-le-Rotrou
  • Orléans
  • Paris
  • Pierre-Bénite
  • Poitiers
  • Rennes
  • Roubaix
  • Saint-Cyr-sur-Loire
  • Saint-Lô
  • Saint-Mandé
  • Saint-Nazaire
  • Saint-Priest-en-Jarez
  • Saint-Quentin
  • Saintes
  • sisteron
  • Strasbourg
  • Thonon-les-Bains
  • Toulouse
  • Tours
  • Valenciennes
  • Vandœuvre-lès-Nancy
  • Villeneuve-sur-Lot
  • Échirolles
  • Épagny-Metz-Tessy
Trial Identifier:

NCT02608112 ML29256

      Show trial locations

      The source of the below information is the publicly available website It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT02608112 , ML29256 Trial Identifier
      Methotrexate, Tocilizumab Treatments
      Rheumatoid Arthritis Condition
      Official Title

      Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants at least 18 years old
      • Participants with moderate to severe RA not previously treated with TCZ (Intravenous [IV] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)
      Exclusion Criteria
      • Participants taking part in a clinical trial on RA at the time of inclusion
      • Participants with a contra-indication to TCZ SC therapy

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now